Skip to contentC
CV Sciences, Inc.
C
CVSICV Sciences, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$4.97M$4.97Mderived−4.4% vs Q4 2020 Net Income-$8.86M-$8.86MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CV Sciences, Inc. · CIK 1510964 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,610,000−27.5% Operating Incomederived-$8,843,000N/M Operating Cash Flowderived-$1,164,000N/M Free Cash Flowderived-$1,164,000N/M Margins · derivedGross margin32.4%−10.3 pt vs Q4 2020
Operating margin-178.0%+4.1 pt vs Q4 2020
Net margin-178.2%+0.5 pt vs Q4 2020
ended Dec 31, 2021 · filed Apr 4, 2022 · 94 d after period end